| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Davidson Michael H. | Chief Executive Officer, Director | C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS | /s/ Michael H. Davidson | 26 Feb 2026 | 0001573785 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NAMS | Ordinary Shares | Options Exercise | +64,708 | +14% | 524,567 | 24 Feb 2026 | Direct | F1 | ||
| transaction | NAMS | Ordinary Shares | Sale | $2,223,693 | -61,547 | -12% | $36.13 | 463,020 | 24 Feb 2026 | Direct | F2 |
| transaction | NAMS | Ordinary Shares | Sale | $115,250 | -3,161 | -0.68% | $36.46 | 459,859 | 24 Feb 2026 | Direct | F3 |
| transaction | NAMS | Ordinary Shares | Options Exercise | +58,253 | +13% | 518,112 | 25 Feb 2026 | Direct | F1 | ||
| transaction | NAMS | Ordinary Shares | Sale | $1,633,212 | -46,517 | -9% | $35.11 | 471,595 | 25 Feb 2026 | Direct | F4 |
| transaction | NAMS | Ordinary Shares | Sale | $375,279 | -10,436 | -2.2% | $35.96 | 461,159 | 25 Feb 2026 | Direct | F5 |
| transaction | NAMS | Ordinary Shares | Sale | $47,684 | -1,300 | -0.28% | $36.68 | 459,859 | 25 Feb 2026 | Direct | F6 |
| transaction | NAMS | Ordinary Shares | Options Exercise | +183,332 | +40% | 643,191 | 26 Feb 2026 | Direct | F1 | ||
| transaction | NAMS | Ordinary Shares | Sale | $5,562,671 | -165,408 | -26% | $33.63 | 477,783 | 26 Feb 2026 | Direct | F7 |
| transaction | NAMS | Ordinary Shares | Sale | $617,303 | -17,924 | -9.3% | $34.44 | 174,144 | 26 Feb 2026 | Direct | F8, F9 |
| holding | NAMS | Ordinary Shares | 285,715 | 24 Feb 2026 | By GRAT | F9 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NAMS | Option (right to buy) | Options Exercise | $0 | -64,708 | -6.5% | $0.000000 | 924,559 | 24 Feb 2026 | Ordinary Shares | 64,708 | Direct | F1, F10 | |
| transaction | NAMS | Option (right to buy) | Options Exercise | $0 | -58,253 | -6.3% | $0.000000 | 866,306 | 25 Feb 2026 | Ordinary Shares | 58,253 | Direct | F1, F10 | |
| transaction | NAMS | Option (right to buy) | Options Exercise | $0 | -183,332 | -21% | $0.000000 | 682,974 | 26 Feb 2026 | Ordinary Shares | 183,332 | Direct | F1, F10 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The exercise price of the option is EUR 1.16392. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.43 to $36.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| F3 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.43 to $36.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| F4 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.57 to $35.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| F5 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.57 to $36.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| F6 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.58 to $36.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| F7 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.34 to $34.33 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| F8 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.35 to $34.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| F9 | The amount reported in Column 5 reflects the transfer of 285,715 ordinary shares from the Reporting Person to the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the "GRAT") on February 26, 2026, which transfer was exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934. The Reporting Person is the sole annuitant and trustee of the GRAT. |
| F10 | The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |